Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach ; day:14 ; month:6 ; year:2021 ; pages:1-14
Clinical pharmacokinetics ; (14.6.2021), 1-14
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-021-01041-x
- URN
-
urn:nbn:de:101:1-2021100419232133483295
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kneller, Lisa Alina
- Zubiaur, Pablo
- Koller, Dora
- Abad Santos, Francisco
- Hempel, Georg
- SpringerLink (Online service)
Ähnliche Objekte (12)
Precision dosing of risperidone and aripiprazole in the treatment of schizophrenia using a physiologically based pharmacokinetic approach: a focus on the genetic polymorphism of CYP2D6
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Aripiprazole as protector against COVID-19 mortality
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports
Aripiprazole in Tardive Dyskinesia: Is it a Safe Choice?
Precision dosing of risperidone and aripiprazole in the treatment of schizophrenia using a physiologically based pharmacokinetic approach: a focus on the genetic polymorphism of CYP2D6
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Aripiprazole as protector against COVID-19 mortality
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports
Aripiprazole in Tardive Dyskinesia: Is it a Safe Choice?
Precision dosing of risperidone and aripiprazole in the treatment of schizophrenia using a physiologically based pharmacokinetic approach: a focus on the genetic polymorphism of CYP2D6
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Aripiprazole as protector against COVID-19 mortality
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports